Innovation in the pharmaceutical industry: New estimates of R&D costs.


Autoria(s): DiMasi, JA; Grabowski, HG; Hansen, RW
Cobertura

Netherlands

Data(s)

01/05/2016

Resumo

The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval. The estimated average out-of-pocket cost per approved new compound is $1395 million (2013 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 10.5% yields a total pre-approval cost estimate of $2558 million (2013 dollars). When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of 8.5% above general price inflation. Adding an estimate of post-approval R&D costs increases the cost estimate to $2870 million (2013 dollars).

Formato

20 - 33

Identificador

http://www.ncbi.nlm.nih.gov/pubmed/26928437

S0167-6296(16)00029-1

J Health Econ, 2016, 47 pp. 20 - 33

http://hdl.handle.net/10161/12742

1879-1646

Idioma(s)

eng

Relação

J Health Econ

10.1016/j.jhealeco.2016.01.012

Palavras-Chave #Discount rate #Innovation #Pharmaceutical industry #R&D cost #Technical success rates
Tipo

Journal Article